Miti Biosystems GmbH

Miti Biosystems GmbH is an Austrian biotechnology company specialized in the production of polycyclic peptide libraries for the discovery of peptide drugs and mimotopes. The company applies patented platform technology that uses randomization techniques on natural product peptide scaffolds to achieve complete chemical diversity. By starting from biologically evolved scaffolds that have been selected and optimized for biological activity over millions of years, Miti Biosystems aims to accelerate the identification of highly constrained peptides suitable for pharmaceutical development. The company was founded in summer 2014 as a spin-out from the Research Institute for Limnology at the University of Innsbruck, based on the findings of Dr. Guntram Christiansen. It has licensed intellectual property initially developed by Christiansen at the Austrian Academy of Sciences. Miti Biosystems has received non-dilutive financing of approximately €1 million from Austria Wirtschaftsservice (AWS). Miti Biosystems' approach combines ultra-diverse structural libraries with display techniques to enable rapid screening for substances with desired physicochemical properties. The company's focus is on cyclic peptides that are intrinsically optimized for metabolic stability and target recognition, making them advantageous starting points for drug discovery. The company is based in Austria and operates primarily in the European biotechnology and pharmaceutical research market.

Miti Biosystems GmbH was founded in summer 2014 as a spin-out from the Research Institute for Limnology at the University of Innsbruck, Austria. The company is based on the scientific findings of Dr. Guntram Christiansen, who initially developed the underlying intellectual property at the Austrian Academy of Sciences. Miti Biosystems licensed this IP to build its platform for the discovery of highly constrained peptides for pharmaceutical development. The company's core technology applies non-biased randomization techniques to biologically evolved cyclic peptide scaffolds. These scaffolds, having been selected through millions of years of evolution, are intrinsically optimized for metabolic stability and target recognition, making them advantageous starting points for generating diverse peptide libraries. By combining ultra-diverse structural libraries with display techniques, Miti Biosystems enables rapid screening for substances with desired physicochemical properties. In its early years, Miti Biosystems received approximately €1 million in non-dilutive financing from Austria Wirtschaftsservice (AWS), an Austrian federal promotional bank. The company has continued to focus on its patented platform technology for producing polycyclic peptide libraries for peptide drug and mimotope discovery. As of the available information, Miti Biosystems remains an active private biotechnology company based in Austria.

• 2014

  Miti Biosystems GmbH founded in summer 2014 as a spin-out from the Research Institute for Limnology at the University of Innsbruck.

• Licensed intellectual property initially developed by Dr. Guntram Christiansen at the Austrian Academy of Sciences.

• Received approximately €1 million in non-dilutive financing from Austria Wirtschaftsservice (AWS).

Biotechnology company leveraging biologically evolved cyclic peptide scaffolds and patented randomization technology for accelerated peptide drug discovery.

• Polycyclic peptide libraries

  Libraries of polycyclic peptides generated using patented randomization technology on natural product scaffolds.

• Cyclic peptide libraries

  Cyclic peptide libraries containing randomization at every desired position, based on biologically evolved scaffolds.

1. 1Miti Biosystems — Polycyclic Peptides Unlimitedmitibio.com
2. 2About us — Miti Biosystemsmitibio.com
3. 3Miti Biosystems GmbHwikidata.org